Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 6/20 | 0.53 |
| ▸ | PPARA | Q07869 | 5/20 | 0.53 |
| ▸ | TERT | O14746 | 3/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | PPARD | Q03181 | 3/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | FABP4 | P15090 | 2/20 | 0.53 |
| ▸ | F7 | P08709 | 2/20 | 0.53 |
| ▸ | F3 | P13726 | 2/20 | 0.53 |
| ▸ | GMNN | O75496 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2552368 | 1.00 | FASN (0.65) | FASNKDM4EMAPTABCC4PPARG | |
| SCHEMBL2553542 | 1.00 | FASN (0.65) | FASNKDM4EMAPTABCC4PPARG | |
| SCHEMBL7166391 | 1.00 | FASN (0.65) | FASNKDM4EMAPTABCC4PPARG | |
| SCHEMBL2552994 | 1.00 | FASN (0.65) | FASNKDM4EMAPTABCC4PPARG | |
| SCHEMBL2553360 | 1.00 | FASN (0.65) | FASNKDM4EMAPTABCC4PPARG | |
| SCHEMBL2553543 | 1.00 | FASN (0.65) | FASNKDM4EMAPTABCC4PPARG | |
| SCHEMBL2556926 | 1.00 | FASN (0.65) | FASNKDM4EMAPTABCC4PPARG | |
| SCHEMBL2556924 | 1.00 | FASN (0.65) | FASNKDM4EMAPTABCC4PPARG | |
| SCHEMBL2552370 | 1.00 | FASN (0.65) | FASNKDM4EMAPTABCC4PPARG | |
| SCHEMBL2551099 | 1.00 | FASN (0.65) | FASNKDM4EMAPTABCC4PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605641-B2 | Treatment of disease or disease symptoms mediated by eicosanoid 20-hydroxyeicosatetraenoic acid (20-HETE) a potent constrictor of renal, cerebral and skeletal muscle arterioles | MCW RESEARCH FOUNDATION | 2003-08-12 | — | — | US | disclosed |
| US-6596769-B2 | Supplying 20-hydroxyeicosatetraenoic acid (20-HETE) agonist or antagonist for reducing a patient's vascular diameter or preventing 20-HETE from reducing vascular diameter | MCW RESEARCH FOUNDATION | 2003-07-22 | — | — | US | disclosed |
| EP-1056449-B1 | 20-HETE ANTAGONISTS AND AGONISTS | MCW RES FOUND INC (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020072534-A1 | 20- Hete antagonists and agonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-06-13 | — | — | US | disclosed |
| US-6395781-B1 | REDUCING VASCULAR DIAMETER | MCW RESEARCH FOUNDATION | 2002-05-28 | — | — | US | disclosed |
| US-20020049244-A1 | 20-HETE antagonists and agonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-04-25 | — | — | US | disclosed |
| EP-1056449-A2 | 20-HETE ANTAGONISTS AND AGONISTS | MCW Research Foundation, Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043310-A2 | 20-HETE ANTAGONISTS AND AGONISTS | MCW RESEARCH FOUNDATION, INC. (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072534-A1 | 20- Hete antagonists and agonists | ALOX5, ALOX15, ALOX15B | FASN 240/4885KDM4E 1409/4885MAPT 4875/4885 |
| US-20020049244-A1 | 20-HETE antagonists and agonists | ALOX5, ALOX15, ALOX15B | FASN 137/4885KDM4E 1617/4885MAPT 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.